Dr Robert Sambursky, Chairman, RPS

Robert Sambursky has been a member of RPS’s executive leadership team as the Chief Medical Officer and served on the company’s Board of Directors since co-founding the company in 2004. In addition, he served as both President and Executive Chairman before being appointed the additional roles of CEO and Chairman. Sambursky currently serves on several pharmaceutical advisory boards.

He earned his BA from Brown University, MA from Boston University, and MD from Boston University School of Medicine. Sambursky completed his medical internship at Mount Auburn Hospital and both his ophthalmology residency and cornea fellowship at Wills Eye Hospital in Philadelphia
Doris-Ann Williams MBE, Chief Executive, BIVDA

Doris-Ann Williams has been Chief Executive of BIVDA since October 2001. She has more than 30 years' experience working in the IVD sector and has had a variety of experience; initially in R&D and subsequently in commercial roles including international responsibilities.

Doris-Ann represents the IVD industry to a range of stakeholders, and sits on the boards and steering groups of a variety of initiatives. These include the Ministerial Medical Technology Strategy Group, with Innovate UK, the UK Pharmacogenetics and Stratified Medicine Network, and the Parliamentary and Science Committee as Vice-President.

Doris-Ann works closely with EDMA and other global IVD industry associations. She was awarded an MBE in January 2011 and was recognised as a Friend of the Royal College of Pathologists in November 2012.
Ann Van den Bruel, Associate Professor, University of Oxford

Ann Van den Bruel is an Associate Professor at the University of Oxford, where she leads the NIHR Diagnostic Evidence Cooperative that aims to facilitate the development and evaluation of clinically relevant diagnostics in primary care.

She has conducted various diagnostic studies including large cohort studies, randomised controlled trials and systematic reviews. Ann has a particular interest in tests that can support the early detection of serious infections in children.
Ben Hendry, Outreach and Engagement Manager, NICE Office for Market Access

Ben Hendry is the Outreach and Engagement Manager for the NICE Office for Market Access. Ben graduated with a History degree in 2004 and spent the next few years working in the Communications team at the Information Commissioner's Office.

Ben has over ten years of experience at NICE; joining in 2007 as an E-media Officer working on the NICE website. In October 2009, he moved to the Centre for Health Technology Evaluation Directorate as the Topic Selection Project Manager. After six years working in Topic Selection, Ben was promoted and moved to NICE's Office for Market Access in September 2015.
Rosanna Peeling, Professor/Chair of Diagnostics Research, London School of Hygiene and Tropical Medicine, Director of the International Diagnostic Centre (IDC).

Rosanna Peeling is currently Professor/Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine and Director of the International Diagnostic Centre (IDC). Trained as a medical microbiologist, she was Research Coordinator and Head of Diagnostics Research at the WHO in Geneva and Chief of the National Laboratory for Sexually Transmitted Diseases in Canada before assuming her current position.

Her research focuses on defining unmet diagnostic needs and facilitating test development, evaluation and implementation in developing countries. She established the IDC to advocate the value of diagnostics, foster innovation, and accelerate access to quality-assured diagnostics to improve global health and combat antimicrobial resistance (AMR).

She is on the Prize Advisory Panel for the UK Longitude Prize, the European Commission Horizon 2020 AMR Prize and the Global AMR Innovation Fund. She was invited to speak at AMR events at the 2016 UN General Assembly, the 2017 World Economic Forum in Davos and the 2017 World Health Assembly on the use of diagnostics to reduce AMR.
Dr Mike Hubank, Head of Clinical Genomics, Royal Marsden Hospital

Dr Mike Hubank is Head of Clinical Genomics (Research) at the Royal Marsden Hospital, with an honorary Readership in Translational Genomics at the Institute for Cancer Research, London. He leads the Molecular Diagnostics translational research team, establishing new genomics assays, and developing and applying diagnostic testing for clinical trials and research studies across the cancer field.

Dr Hubank previously led UCL Genomics for 16 years, contributing to many publications in fields ranging from cancer to metagenomics. He is particularly interested in implementing genomic testing for circulating tumour DNA in a clinically relevant setting.
Dr Elizabeth Pilling, Consultant Neonatologistand Clinical Lead for the Yorkshire and Humber Neonatal ODN

Dr Elizabeth Pilling is a Consultant Neonatologistand Clinical Lead for the Yorkshire and Humber Neonatal ODN. Dr Pilling has worked at the Jessop wing, Sheffield Neonatology for 8 years. Her special interests are neonatal microbiology and infection control, growth of preterm infants and data analysis. She has been involved in a number of quality improvement projects particularly around reducing central line infection rates but also improving neonatal antimicrobial stewardship.
Dr Wai Lup Wong BA [hons] LLM FRCR FRCP

Dr Wai Lup Wong is Consultant radiologist [cancer diagnostics and nuclear medicine]. with an honorary Senior Lecturership in the Division of Medicine at University College, London. He is chair of the Cancer Diagnostics Clinical Reference Group, NHS England and Clinical Guardian (PET-CT), NHS England.

At St Thomas’ hospital, he took the radiological lead in the team that pioneered computer combination of PET to CT in the head and neck (H&N) and demonstrated the advantage of PET-CT in the assessment of H&N cancer. He has published extensively in cancer diagnostics. One of his main research interest is development of diagnostic pathways to improve the care of people with cancer.
Dr. Elisabeth Adams, Managing Director, Aquarius Population Health Limited

Dr Elisabeth Adams is the Founder and Managing Director of Aquarius Population Health. She studied Psychology as an undergraduate (University of Michigan, BS Hons), Control of Infectious Diseases at Oxford University (MSc), and then received her PhD from the London School of Hygiene and Tropical Medicine. Her thesis on the cost-effectiveness of chlamydia screening in England and her work on sexual health has influenced national and international policy.

Elisabeth founded Aquarius Population Health in response to her passion for making high quality research and consultancy as accessible as possible to her academic, healthcare provider, policy-making and commercial colleagues. She has worked extensively across diagnostics, in particular on developing evidence for the costs, benefits and value of rapid testing and point of care devices. She is also Co-PI on several large NIHR/SBRI grant-funded projects for rapid diagnostics.
Dr Daniel Lasserson GP and Professor of Ambulatory Care, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham

Professor Dan Lasserson is the only Professor of Ambulatory Care in the UK. His research group tackles one of the biggest challenges that healthcare is facing – the delivery of acute medical care, where needs are increasing year by year but the available resources to meet those needs are limited. Both primary and secondary care acute services are increasingly stretched and calls for new models of acute care have come from NHS England, the Royal College of Physicians and the Primary Care Workforce Commission.
Dr Tony Newman-Sanders, Clinical Director, Diagnostic Imaging, NHS England

Tony Newman-Sanders read Medicine at Gonville and Caius College, Cambridge and the Royal London Hospital. He trained in General Medicine at Bart’s, in Renal Medicine and then in Clinical Radiology at St Mary’s Hospital, Paddington.In January 2016 he was appointed the first Medical Director of the Health Innovation Network. He represents the AHSN Network on the Strategic Clinical Reference Group of the National Informatics Board.
Muti Abulafi, Consultant Colorectal Surgeon, Croydon University Hospital

Mr Muti Abulafi is a consultant colorectal surgeon at Croydon University Hospital and chief investigator of the NICE FIT study. He chairs the colorectal pathway group for RM Partners, the cancer alliance for west London. He is a fellow of the Royal College of Surgeons of England and holds a Master of Surgery (MS) degree from the University of London for his research work on the role of intraoperative photodynamic therapy in colorectal cancer. He has a research interest in, and has published on, colorectal cancer and cancer genetics. He is a founder and co-convener of the annual M25 Colorectal Diseases Masterclass supported by the Pelican Cancer Foundation, which teaches young surgeons on all aspects of colorectal surgery.
Dr Vicki Chalker,Head, Respiratory and Vaccine Preventable Bacteria Reference Unit, National Infection Service, Public Health England

Dr Vicki Chalker is Head of the Respiratory and Vaccine Preventable Bacteria Reference Unit at PHE Colindale and is internationally recognised as a world leading Mollicute expert with increasing expertise and remit for a large range of micro-organisms including legionella, streptococci and leptospira. In addition to heading the National Legionella Reference Laboratory (NLRL), she has previously led genomic studies of respiratory and systemic pathogens and formed and led European consortia for specific pathogens. In addition to providing reference services her team focuses on the development and validation of international standard methods for the laboratory diagnosis, increased discrimination and field investigation of pathogens including legionellosis.